LUNG-ROLL: Treatment patterns and costs for people with lung cancer in Canada

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

This project looks at past health records to see how lung cancer is treated and what healthcare it uses for adults in Alberta and Ontario.

Quick facts

• Study type: Observational
• Enrollment: 60000 (estimated)
• Ages: 18 Years to 130 Years
• Sex: All
• Sponsor: AstraZeneca (Industry-sponsored)
• Locations: 2 sites (Calgary, Alberta and 1 other locations)
• Trial ID: NCT07143110 on ClinicalTrials.gov

What this trial studies

LUNG-ROLL is a retrospective cohort using provincial administrative health data from Alberta and Ontario beginning January 1, 2018 to describe contemporary treatment patterns, incidence and prevalence, patient demographics, clinical outcomes, and healthcare resource use and costs among people with lung cancer. Eligible patients are adults diagnosed with lung cancer who had at least 12 months of health insurance coverage before diagnosis and who were residents of Alberta or Ontario at diagnosis, with several exclusions for prior or concurrent other cancers and incomplete records. The study will use linked administrative datasets to capture treatments, hospital and outpatient care, and cost-related billing records to quantify resource use. Results will be presented as summary statistics and temporal trends to inform clinicians, health system planners, and policymakers about real-world care and cost drivers.

Who should consider this trial

Good fit: Adults (18+) diagnosed with lung cancer on or after January 1, 2018 who were residents of Alberta or Ontario at diagnosis and had at least 12 months of prior health insurance coverage, without other cancers in the five years before 2018 or on the same diagnosis date, are included.

Not a fit: People who live outside Alberta or Ontario, were diagnosed before 2018, lack sufficient insurance or administrative records, or have concurrent/very recent other cancers are not represented and are unlikely to benefit directly from this study's findings.

Why it matters

Potential benefit: If successful, the findings could help health systems and clinicians understand real-world treatment patterns and cost drivers to improve resource planning and patient care.

How similar studies have performed: Similar retrospective administrative database studies of lung cancer have been used successfully to describe treatment patterns, outcomes, and costs and to inform policy, though findings vary by region and data completeness.

Eligibility criteria

Inclusion Criteria:

* Patients with lung cancer between January 1, 2018 and end of the Selection Period.
* Patient is 18 years of age or older on diagnosis date.
* Patient has at least 12 months of health insurance coverage prior to the diagnosis date.

Exclusion Criteria:

* Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
* Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
* Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
* Non-Ontario or non-Alberta resident on diagnosis date.

Where this trial is running

Calgary, Alberta and 1 other locations

• Research Site — Calgary, Alberta, Canada (Recruiting)
• Research Site — Toronto, Ontario, Canada (Recruiting)

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center

Conditions Lung Neoplasms; Non-Small-Cell Lung; Small Cell Lung; Epidemiology; Treatment Patterns; Real-World